Beta-blocker pharmacogenomics · Beta-adrenergic receptor sensitivity · Ansprechen auf Betablocker bei Herzinsuffizienz · Beta-Blocker-Therapieansprechen
This is a genetic trait that affects how a dog's cardiovascular system responds to beta-blockers, which are medications commonly used to manage heart failure. In dogs with this genetic variation, the heart muscle may not respond as effectively to these drugs, reducing their ability to control heart rate and blood pressure. It is a pharmacogenomic trait, meaning a genetic factor that specifically influences drug effectiveness rather than causing a disease on its own.
An owner would only notice this trait if their dog is being treated for heart failure, which typically develops in middle-aged to older dogs. Symptoms of a poor response to therapy include persistent coughing, difficulty breathing, and weakness despite receiving medication.
While the genetic trait itself cannot be cured, the underlying heart failure is managed with lifelong veterinary care and tailored medication adjustments. Ongoing cardiac care, specialized monitoring, and alternative drug regimens typically cost between 1,500 and 6,000 EUR.
Estimated range of typical treatment cost. Actual cost depends on severity, clinic and region.
More conditions affecting the Heart.